TTFields Optune Lua - Revision history

MesotheliomaSupport: Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

2026-04-06T09:57:31Z

Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

← Older revision		Revision as of 09:57, 6 April 2026
Line 689:		Line 689:
	<ref name="dandell_treatment">[https://dandell.com/mesothelioma-treatment/ Mesothelioma Treatment Options], Danziger & De Llano, LLP</ref>		<ref name="dandell_treatment">[https://dandell.com/mesothelioma-treatment/ Mesothelioma Treatment Options], Danziger & De Llano, LLP</ref>
	<ref name="dandell_legal">[https://dandell.com/mesothelioma-lawsuits/ Mesothelioma Lawsuits and Legal Options], Danziger & De Llano, LLP</ref>		<ref name="dandell_legal">[https://dandell.com/mesothelioma-lawsuits/ Mesothelioma Lawsuits and Legal Options], Danziger & De Llano, LLP</ref>
	~~<ref name="dandell_diagnosis">[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano, LLP</ref>~~
	~~<ref name="dandell_compensation">[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation and Settlements], Danziger & De Llano, LLP</ref>~~
	~~<ref name="dandell_trust">[https://dandell.com/asbestos-trust-funds/ Asbestos Trust Fund Claims], Danziger & De Llano, LLP</ref>~~
	~~<ref name="dandell_types">[https://dandell.com/types-of-mesothelioma/ Types of Mesothelioma], Danziger & De Llano, LLP</ref>~~
	~~<ref name="dandell_asbestos">[https://dandell.com/asbestos-exposure/ Asbestos Exposure and Health Risks], Danziger & De Llano, LLP</ref>~~
	~~<ref name="dandell_veterans">[https://dandell.com/mesothelioma-veterans/ Mesothelioma and Veterans], Danziger & De Llano, LLP</ref>~~
	<ref name="mlc_treatment">[https://mesotheliomalawyercenter.org/treatment/ Mesothelioma Treatment Overview], Mesothelioma Lawyer Center</ref>		<ref name="mlc_treatment">[https://mesotheliomalawyercenter.org/treatment/ Mesothelioma Treatment Overview], Mesothelioma Lawyer Center</ref>
	<ref name="mlc_clinical_trials">[https://mesotheliomalawyercenter.org/clinical-trials/ Mesothelioma Clinical Trials], Mesothelioma Lawyer Center</ref>		<ref name="mlc_clinical_trials">[https://mesotheliomalawyercenter.org/clinical-trials/ Mesothelioma Clinical Trials], Mesothelioma Lawyer Center</ref>
	~~<ref name="mlc_diagnosis">[https://mesotheliomalawyercenter.org/diagnosis/ Mesothelioma Diagnosis Information], Mesothelioma Lawyer Center</ref>~~
	~~<ref name="mlc_stages">[https://mesotheliomalawyercenter.org/stages/ Mesothelioma Stages and Staging], Mesothelioma Lawyer Center</ref>~~
	~~<ref name="mlc_prognosis">[https://mesotheliomalawyercenter.org/prognosis/ Mesothelioma Prognosis and Life Expectancy], Mesothelioma Lawyer Center</ref>~~
	~~<ref name="mlc_pleural">[https://mesotheliomalawyercenter.org/pleural-mesothelioma/ Pleural Mesothelioma Guide], Mesothelioma Lawyer Center</ref>~~
	<ref name="mesonet_treatment">[https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma Treatment Options], Mesothelioma.net</ref>		<ref name="mesonet_treatment">[https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma Treatment Options], Mesothelioma.net</ref>
	<ref name="mesonet_emerging">[https://mesothelioma.net/emerging-treatments/ Emerging Mesothelioma Treatments], Mesothelioma.net</ref>		<ref name="mesonet_emerging">[https://mesothelioma.net/emerging-treatments/ Emerging Mesothelioma Treatments], Mesothelioma.net</ref>
	<ref name="mesonet_support">[https://mesothelioma.net/mesothelioma-support/ Mesothelioma Patient Support Resources], Mesothelioma.net</ref>		<ref name="mesonet_support">[https://mesothelioma.net/mesothelioma-support/ Mesothelioma Patient Support Resources], Mesothelioma.net</ref>
	~~<ref name="mesonet_clinical">[https://mesothelioma.net/clinical-trials/ Mesothelioma Clinical Trials Information], Mesothelioma.net</ref>~~
	~~<ref name="mesonet_types">[https://mesothelioma.net/types-of-mesothelioma/ Types of Mesothelioma], Mesothelioma.net</ref>~~
	<ref name="mesoatty_treatment">[https://mesotheliomaattorney.com/mesothelioma-treatment/ Mesothelioma Treatment Advances], MesotheliomaAttorney.com</ref>		<ref name="mesoatty_treatment">[https://mesotheliomaattorney.com/mesothelioma-treatment/ Mesothelioma Treatment Advances], MesotheliomaAttorney.com</ref>
	<ref name="mesoatty_options">[https://mesotheliomaattorney.com/mesothelioma-legal-options/ Mesothelioma Legal Options], MesotheliomaAttorney.com</ref>		<ref name="mesoatty_options">[https://mesotheliomaattorney.com/mesothelioma-legal-options/ Mesothelioma Legal Options], MesotheliomaAttorney.com</ref>
	~~<ref name="mesoatty_compensation">[https://mesotheliomaattorney.com/mesothelioma-compensation/ Mesothelioma Compensation Guide], MesotheliomaAttorney.com</ref>~~
	<ref name="novocure_patient">[https://www.novocure.com/patient-support/ NovoCure Patient Support and Financial Assistance], NovoCure</ref>		<ref name="novocure_patient">[https://www.novocure.com/patient-support/ NovoCure Patient Support and Financial Assistance], NovoCure</ref>
	</references>		</references>

MesotheliomaSupport: Add differentiated triple GEO format

2026-03-08T22:11:28Z

Add differentiated triple GEO format

@@ Line 57: / Line 57: @@
 | style="padding:10px;" | MPM, GBM (new & recurrent), NSCLC
 |}
 == Key Facts ==
@@ Line 62: / Line 75: @@
 {| class="wikitable" style="width:100%; border-collapse:collapse; margin:1em 0;"
 |-
-! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: TTFields / Optune Lua for Mesothelioma
+! style="background:#1a5276; color:white; padding:10px;" | Metric
 |-
-| style="padding:15px;" |
+| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Dermatologic Adverse Events
-* TTFields are low-intensity alternating electric fields (150 kHz for mesothelioma) that disrupt cancer cell division while sparing normal cells<ref name="mechanisms_nature" />
+| style="padding:10px; border-bottom:1px solid #dee2e6;" | 58% any grade; 53% grade 1-2 dermatitis; 6% grade 3-4 (meta-analysis, N=192)<ref name="skin_guidance" /><ref name="ceresoli_review" />
-* The STELLAR trial demonstrated '''18.2-month median overall survival''' in 80 patients with unresectable MPM — a 50% improvement over the 12.1-month historical control with chemotherapy alone<ref name="ceresoli_review" />
+|-
-* FDA granted Humanitarian Device Exemption approval on '''May 23, 2019''' — the first new mesothelioma treatment approved since pemetrexed in 2004<ref name="fda_hde" /><ref name="medtechdive" />
+| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approval
-* Patients with '''epithelioid histology''' achieved median OS of '''21.2 months''' versus 12.1 months for non-epithelioid subtypes<ref name="ceresoli_review" />
+| style="padding:10px; border-bottom:1px solid #dee2e6;" | May 23, 2019 — Humanitarian Device Exemption (H180002) for unresectable MPM<ref name="fda_hde" />
-* The only device-related adverse event is localized skin irritation — '''66% grade 1-2''' and '''5% grade 3''' — with no systemic toxicity<ref name="ceresoli_review" />
+|-
-* The second-generation Optune Lua weighs '''1.2 kg''' (down from 2.7 kg) and is worn continuously for at least '''18 hours per day'''<ref name="ceresoli_review" />
+| style="padding:10px; font-weight:bold;" | Device Compliance (STELLAR)
-* More than '''110 U.S. hospitals''' are certified to provide TTFields therapy for mesothelioma<ref name="novocure_history" />
+| style="padding:10px;" | Median 16.3 hours/day during first 3 months; recommended minimum 18 hours/day (75%)<ref name="ceresoli_review" /><ref name="ilcn_practice" />
 |}
@@ Line 579: / Line 613: @@
 TTFields therapy is approved for adults with unresectable, locally advanced or metastatic malignant pleural mesothelioma. Patients must not have implanted electronic medical devices (pacemakers, defibrillators), known sensitivity to conductive gels, or require supplemental oxygen. Treatment is initiated at certified centers where NovoCure support specialists provide training for patients and caregivers.<ref name="fda_hde" /><ref name="fda_ssed" />
 == Related Pages ==

MesotheliomaSupport: Create comprehensive TTFields/Optune Lua medical wiki page — STELLAR trial, FDA HDE approval, mechanism, treatment protocol, side effects, cost, guidelines

2026-03-04T02:37:47Z

Create comprehensive TTFields/Optune Lua medical wiki page — STELLAR trial, FDA HDE approval, mechanism, treatment protocol, side effects, cost, guidelines

Show changes